Catalent
CTLT
$53.79
Share price
0.34%
Change (1 day)
45.38%
Change (1 year)
Categories
Catalent is an American pharmaceutical contract research and development company.
Catalent (CTLT) - Total assets
Total assets on the balance sheet as of March 2024 : $9.87 B
According to Catalent's latest financial reports the company's total assets are $9.87 B. A company’s total assets is the sum of all current and non-current assets, such as inventories, cash and cash equivalents, properties and equipment.
Catalent - Total assets on balance sheet (from 2013 to 2024)
Total assets by year
| Year | Total assets | Change |
|---|---|---|
| 2023-06-30 | $10.77 B | 2.56% |
| 2022-06-30 | $10.50 B | 15.32% |
| 2021-06-30 | $9.11 B | 17.17% |
| 2020-06-30 | $7.77 B | 25.76% |
| 2019-06-30 | $6.18 B | 36.48% |
| 2018-06-30 | $4.53 B | 31.17% |
| 2017-06-30 | $3.45 B | 11.75% |
| 2016-06-30 | $3.09 B | -1.5% |
| 2015-06-30 | $3.13 B | 1.56% |
| 2014-06-30 | $3.09 B | 4.77% |
| 2013-06-30 | $2.94 B | -6.04% |
| 2012-06-30 | $3.13 B |
Total Assets for similar companies or competitors
| Company | Total assets | differencediff. | Country |
|---|---|---|---|
 Supernus Pharmaceuticals
SUPN | $1.30 B | -86.80% | 🇺🇸 USA |
 Jazz Pharmaceuticals JAZZ | $11.32 B | 14.66% | 🇮🇪 Ireland |
 Aerie Pharmaceuticals AERI | $0.37 B | -96.20% | 🇺🇸 USA |
 Intercept Pharmaceuticals
ICPT | $0.39 B | -96.02% | 🇺🇸 USA |